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INTRODUCTION
Infantile hemangioma (IH) is a common vascular tumor in chil-
dren. Schupp et al. [1] reported an estimated incidence rate in 
Asia of one in 125 persons annually. Female infants are more 
frequently affected than are male infants [2]. The disease is 
caused by an abnormal proliferation of endothelial cells of the 
capillary vessels and typically occurs at 3 to 4 weeks of age, 
peaking at 6 to 7 months of age, in the proliferative phase. After 
this period, the size of the tumor rarely decreases naturally, al-
though its color can suddenly become less livid [3]. Most IHs 
are diagnosed via patient history and physical examination. In 
addition, imaging studies, such as Doppler ultrasound and mag-
netic resonance imaging (MRI), can characterize the location 
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and extent of cutaneous and extracutaneous hemangiomas. 
MRI can also help differentiate IHs from high-flow vascular le-
sions such as arteriovenous malformations. Ultrasonography is 
useful for differentiating hemangiomas from other deep dermal 
or subcutaneous structures, such as cysts, pilomatrixomas, and 
lymph nodes [4].
Although hemangiomas are not routinely biopsied because 
the diagnosis can generally be made clinically, specimens may 
be evaluated for tissue-specific immunohistochemical markers, 
such as GLUT-1, merosin, Fc-gamma-RII, and Lewis Y anti-
gens. These markers can differentiate IHs (positive staining for 
all markers) from other vascular neoplasms and malformations 
[5,6].
Most IHs are small and self-limiting; however, complicated 
IHs with accompanying bleeding or infection may impact vital 
structures, such as the eye or airway, and medical or surgical 
treatment is therefore indicated in such cases [7]. Furthermore, 
the efficacies of existing treatments vary, and all have associated 
safety concerns [8-10]. Systemic glucocorticoids are the prima-
ry treatment for complicated IHs, with interferon-α and vincris-
tine used for lesions that do not respond to glucocorticoid ther-
apy [10,11].
In 2008, Leaute-Labreze et al. [12] reported the first case in 
which propranolol was administered for the treatment of ob-
structive hypertrophic myocardiopathy in a 1-month-old infant 
who had undergone treatment with steroids. Thereafter, treat-
ing IH with propranolol was deemed effective, with a negligible 
frequency of side effects. Propranolol is a nonselective beta-
blocker that is used in patients of all ages with hypertension and 
various cardiac diseases. It is also known to be safe for adminis-
tration in infants [13].
The proposed mechanisms of the effects of propranolol on IH 
include the inhibition of tumor growth and angiogenesis, as well 
as vasoconstriction [14]. Its known side effects include hypo-
tension, bradycardia, bronchospasm, hypoglycemia, and diar-
rhea [12]. However, studies of the effects of propranolol on in-
fant growth and development after its prolonged administration 
are limited, as are studies of the acute side effects mentioned 
above [15,16]. The optimal duration of propranolol treatment 
in cases of IH has not yet been established; its long-term admin-
istration ( > 1 year) may be required, depending on tumor size 
and treatment response. Many studies of IH have been pub-
lished, but few have reported objective measures of treatment 
response. We thus measured the change of color and size of the 
lesions to evaluate their response to treatment. We also describe 
our experience with propranolol dosage and side effects in 23 
IH patients who were treated with propranolol. 
METHODS
Research ethics approval was obtained from the Institutional 
Review Board at Severance Hospital (Approval No. 4-2017-
1158). Informed consent was obtained from all patients or their 
representatives for inclusion in this study.
We evaluated 29 infants with newly diagnosed IH who were 
given propranolol at a dosage of 3 mg/kg/day, given as two di-
vided doses, between 2015 and 2017, at a tertiary care hospital. 
Six patients were excluded from the final analysis because of a 
lack of follow-up visits.
In a retrospective study based on computerized medical re-
cords, the charts were reviewed for sex, age, location of the hem-
angioma, response to treatment as determined by the analysis of 
photos, age of the patient at the beginning of therapy, duration 
of therapy, complications, and adverse effects. We used pro-
pranolol after an evaluation of the cardiac status of each infant 
for the treatment of IH in an outpatient clinic. 
To assess cardiac status for pediatric cardiac outpatient care, 
electrocardiography and echocardiography were conducted. 
Additional imaging studies (ultrasonography or MRI) were 
conducted if necessary. 
The oral administration of propranolol was begun during the 
next outpatient clinic visit after the evaluation of cardiac status 
and imaging studies were complete. Patients’ caregivers were in-
structed to cease administering propranolol if severe coughing, 
dyspnea, vomiting, or diarrhea developed during treatment. 
Follow-up visits were initially scheduled 2 weeks after the initia-
tion of therapy and then monthly thereafter. Visits were also en-
couraged in case of any complications. We determined that the 
duration of treatment would be dependent on the response to 
treatment. 
Patients were evaluated regularly in the outpatient clinic. Pa-
tients were photographed prior to the administration of pro-
pranolol and at 3, 6, 9, and 12 months after treatment, with a 
commercial digital camera and a digital camera equipped with 
the Antera 3D system (Miravex, Dublin, Ireland), which enables 
analyses of size and color from the chromatic aberration values 
(L, a, and b values). These values express color as three numeri-
cal values: L for lightness and a and b for the green-red and blue-
yellow color components, respectively [17]. The a-value was 
measured in our study for assessing the redness of the lesions. 
To assess general aesthetic outcomes and the overall improve-
ment in the appearance of the hemangioma after treatment, we 
measured and compared the initial and final a-values and the 
size of the hemangiomas. 
We further analyzed changes in color and size using four vari-
ables: sex, number of hemangiomas, location of the hemangio-
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ma, and the age of patients at the start of treatment. The starting 
age was divided into two groups: before and after 6 months after 
birth. The location of hemangiomas was also divided into two 
groups: the head and neck group and the non-head and neck 
group. Furthermore, patients were divided into two groups by 
the number of hemangiomas: group 1 included patients with 
only a single hemangioma, whereas group 2 included patients 
with two or more hemangiomas.
Statistical tests were used to analyze the results. The normality 
of the distribution of the groups was assessed using the Shapiro-
Wilk test. Statistical analyses were performed using the t-test for 
independent samples and the Mann-Whitney U-test. A P-value 
less than 0.05 was considered to indicate statistical significance, 
and statistical analyses were performed using SPSS 15.0.1 for 
Windows (SPSS Inc., Chicago, IL, USA).
RESULTS
In the present study, we included 23 children who were diag-
nosed as having IH and who were referred for propranolol treat-
ment. The mean age of the patients at the initiation of treatment 
was 6.5 ± 3.6 months. The average follow-up period was 7.0 ±  
3.2 months. There were three male and 20 female patients. 
Common locations were the head and neck (13 cases, 56.5%), 
trunk (four cases, 17.4%), extremities (three cases, 13.0%), and 
combined locations (three cases, 13.0%). We divided patients 
into two groups based on the number of hemangiomas. Group 
1, which included patients with only a single hemangioma, 
comprised 19 patients, whereas group 2, which included pa-
tients with two or more hemangiomas, was composed of four 
patients (Figs. 1 and 2).
The response to treatment was assessed in terms of color and 
size using the Antera 3D system (Miravex). At the time of the 
initial diagnosis, the average measured a-value was 39.7 ± 7.9. 
The average final a-value was 17.0 ± 14.5. The difference be-
tween the two values was calculated to assess the response of 
treatment in terms of color fading. The mean change of the a-
value was 22.7 ± 15.0. Overall, the a-value decreased.
The Shapiro-Wilk test was performed to test the normality of 
the size-related data. The P-value was less than 0.05, so we con-
cluded that the data were not normally distributed. The median 
initial size of the IHs was 115.0 mm2 (range, 4.0–1,517.0 mm2) 
and the median final size was 56.0 mm2 (range, 1.0–891.0 
mm2). The percent change in size was calculated as the differ-
ence between the initial size and the final size divided by the ini-
tial size. The median percent change in size was 32.3% (range, 
1.1%–92.6%) (Table 1).
When color fading was analyzed by sex, no significant differ-
ence was found in the initial average between male patients 
(46.1 ± 1.1) and female patients (38.8 ± 8.1) (P > 0.05). How-
Fig. 1. Infantile hemangioma on the anterior neck
Patient 3. (A) At 3 months of age, 
1 day prior to treatment with 3 
mg/kg/day of propranolol. (B) Two 
months after propranolol treat-
ment. (C) Six months after pro-
pranolol treatment. (D) Ten months 
after propranolol treatment. 
A
C
B
D
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ever, there was a statistically significant difference according to 
sex in the final a-value, indicating color, and the color change. In 
male patients, the final a-value was lower (P < 0.001) and the 
color change was greater than in female patients (P < 0.001). 
Similar results were found for the number of hemangiomas; 
group 1 showed a lower final a-value (P < 0.001) and a greater 
color change than group 2 (P < 0.001). No other statistically 
significant differences were found in the analyses according to 
the location of the hemangioma and the age of patients at the 
start of treatment (Table 2). 
In an analysis of the response to treatment based on size 
change according to the number of hemangiomas, group 1 
showed a significantly greater size change (median, 49.5%; 
range, 1.1%–92.6%) than group 2 (median, 12.1%; range, 
4.0%–16.0%) Additionally, the change in size in patients who 
started treatment before 6 months of age (median, 62.3%; range 
3.0%–93.0%) was greater than in their counterparts (median, 
15.8%; range, 1.0%–79.0%; P < 0.001). No other statistically 
significant differences were found in the analyses according to 
sex and the location of the hemangioma (Table 3). 
No severe adverse events were noted in any patient. We ob-
served mild adverse effects (diarrhea or mild fever) that were 
tolerated without the need to discontinue treatment (Table 4).
DISCUSSION
Propranolol is widely used for the effective treatment of IH, 
with a good response rate compared with prednisolone, which 
is the conventional treatment [18]; in our experience, it also has 
a good safety profile. Propranolol was the first β-adrenergic re-
ceptor antagonist introduced for the treatment of angina. It is 
known to reversibly bind β1 and β2 receptors, reducing heart 
rate and cardiac output, and causing peripheral vasoconstriction 
soon after administration [19]. Although the mechanism of the 
effects of propranolol on IH remain unclear, some studies have 
reported that vasoconstriction plays a major role in lesion im-
provement [20], appearing to soften lesions and make them less 
livid. Moreover, the late effects of propranolol, which are evi-
dent several days after administration, include lesion improve-
ment via the inhibition of proangiogenic signals, such as vascu-
lar endothelial growth factor and basic fibroblast growth factor, 
and the stimulation of microvascular endothelial cell apoptosis 
[21]. 
The determination of the therapeutic dose of propranolol ap-
pears to differ for each hospital. According to Kim et al. [22], 
treatment with propranolol generally begins at admission, with 
0.5 mg/kg/day administered on the first day of treatment, and 1 
mg/kg/day given on the second day. If no side effects are ob-
served on the third day, the final treatment dose is increased to 2 
Fig. 2. Infantile hemangioma on the right cheek
Patient 4. (A) At 3 weeks of age. 
(B) Three months after the initia-
tion of therapy with 3 mg/kg/day 
of propranolol. (C) Six months of 
age. (D) Residual hemangioma at 
11 months of age. 
A
C
B
D
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mg/kg/day (oral administration 3 times per day every 8 hours), 
and the patient is discharged. Schupp et al. [1] reported that pa-
tients admitted to the hospital were given a dose of 1 mg/kg/
day for 3 days. If no specific adverse events were observed, the 
dose was increased to 2 mg/kg/day, and the patient was dis-
charged with this final dose. In other words, it is common to be-
gin with a small dose of the drug initially and to gradually in-
crease the dose over time. Leaute-Labreze et al. [12] reported 
that their most effective treatment involved a 6-month adminis-
tration of propranolol at a dose of 3 mg/kg/day; thus, we pre-
scribed 3 mg/kg/per day as our initial dose. In our experience, 
there were no major side effects in the 23 patients, except for 3 
cases with minor problems such as diarrhea and fever. 
In a large study of 1,264 IHs by Wedgeworth et al. [23], elec-
trocardiography and echocardiography were not necessary for 
the detection of cardiovascular side effects during treatment 
with propranolol. Leaute-Labreze et al. [12] reported that ad-
verse events related to propranolol (hypoglycemia, hypotension, 
bradycardia, and bronchospasm) did not occur frequently, with 
no significant differences observed between the placebo and 
treatment groups. However, Holland et al. [16] reported a case 
of hypoglycemia and recommended the discontinuation of pro-
pranolol therapy when accompanied by reduced dietary intake.
Noticeably, previous studies used subjective methods to assess 
the perceptible aesthetic treatment results. The reliability of 
subjective assessments is affected by several factors, such as the 
evaluator’s prejudices, variation in lighting conditions, and even 
the emotional status of the infant. Thus, a subjective analysis 
can produce only partially reliable clinical implications. In our 
series, we used the objectively measured parameters of color dif-
ference and size, which were calculated with a digital camera 
and the Antera 3D system.
Interestingly, the response to propranolol was significantly low-
er in patients with a larger number of lesions than in patients with 
a smaller number of lesions in terms of color and size change. 
This finding suggests that propranolol does not effectively inhibit 
abnormal endothelial cell proliferation and angiogenesis, espe-
cially in patients with a large number of hemangiomas. 
Male patients showed a greater color change (P < 0.001), 
whereas there was no sex difference in size changes (P < 0.001). 
The age at the start of treatment did not show a significant rela-
tionship with color change (P < 0.001), but patients who were 
treated before 6 months after birth showed a significantly great-
er size change than their counterparts (P < 0.001). 
Corticosteroids were initially discovered to induce the acceler-
ated regression of proliferating IHs in the 1960s [10,24] and 
have been considered the first-line treatment of IH for over 40 
years [25]. However, because of recent clinical successes using 
the beta-blocker propranolol, the recommended first-line treat-
ment for these lesions is changing.
Izadpanah et al. [18] compared propranolol and corticoste-
roids in terms of their treatment response rates, demonstrating 
that the response to propranolol was significantly better (97.3% 
vs. 71.0%, respectively; P < 0.001), consistent with our study 
findings that 21 out of 23 patients responded to the treatment 
(91.3%). In their meta-analysis of results related to corticoste-
roid use, the most common side effects reported were altered 
growth (6%) and development of a moon face (5%). Other re-
ported side effects included osteoporosis, fungal infections, and 
hypertension. Side effects were encountered in 475 of 2,697 pa-
tients (17.6%). Meanwhile, 96 of 699 patients (13.7%) experi-
enced side effects after propranolol therapy. The complication 
rate of steroid therapy was thus higher than that associated with 
propranolol [18]. The side effects observed at our institution 
were primarily gastrointestinal problems and fever (17.3%); al-
though this rate was high, these complications may not have 
been directly related to propranolol treatment. 
This study has limitations in that the number of patients in 
each group was relatively small; the inclusion of additional cases 
would improve the significance of our findings. In addition, fur-
ther large-scale studies are needed to clarify the effects of pro-
pranolol on infant growth and development after long-term pro-
pranolol treatment. Another limitation is a lack of randomized 
controlled trials comparing propranolol therapy for IH with a 
more conservative treatment. Randomized controlled trials with 
a set dosage, duration of therapy, and appropriate follow-up are 
necessary to validate the observed therapeutic benefits of pro-
pranolol. The examined factors of the follow-up period, age at 
the initiation of treatment, treatment duration, and patient 
weight could influence the response to propranolol therapy. It is 
thus necessary to control for these factors in future studies. 
In conclusion, propranolol is efficacious and has a good safety 
profile for the treatment of IH. A short duration of treatment 
( < 6 months) at a dose of 3 mg/kg/day is able to stabilize and 
induce regression in certain IH patients. In patients with a single 
lesion, the response to treatment was better in terms of color 
fading and size reduction. Furthermore, male patients respond-
ed better to propranolol treatment in terms of color fading than 
female patients, and starting treatment before 6 months after 
birth was more advantageous for size reduction.
NOTES
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